| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/08/2004 | WO2003045965A3 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
| 01/08/2004 | WO2003039382A3 System for processing tissue |
| 01/08/2004 | WO2003020876A3 Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| 01/08/2004 | WO2002099036A3 Inhibition of neurodegeneration |
| 01/08/2004 | WO2002078624A3 Aerosol administration of interleukin-2 liposomes |
| 01/08/2004 | WO2002060524A9 Enhanced ultrasound detection with temperature dependent contrast agents |
| 01/08/2004 | WO2002056864A3 Differential delivery of nitric oxide |
| 01/08/2004 | WO2002053130A3 Sustained release drug delivery devices with coated drug cores |
| 01/08/2004 | WO2001079524A3 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
| 01/08/2004 | WO2001066123A3 Composition consisting of phy906 and chemotherapeutic agents |
| 01/08/2004 | WO1999040955A3 Pressure sensitive adhesive matrix patch for the treatment of onychomycosis |
| 01/08/2004 | US20040006177 Aggregate-forming agent |
| 01/08/2004 | US20040006146 Homogenous, mass-producible, higher strength, resorbable implants with large pores |
| 01/08/2004 | US20040006140 Controlled release arginine formulations |
| 01/08/2004 | US20040006125 Bone growth compositions and methods |
| 01/08/2004 | US20040006111 Transmucosal delivery of proton pump inhibitors |
| 01/08/2004 | US20040006109 Proton pump inhibitors and liquid vehicle having a pH greater than 6.5 and a viscosity sufficient to maintain a uniform suspension |
| 01/08/2004 | US20040006072 For therapy of general anxiety disorder, anxiety associated with depression, panic disorder and panic attacks |
| 01/08/2004 | US20040006048 For prophylaxis and therapy of illnesses in which lipidperoxidation has role, food, beverages, health |
| 01/08/2004 | US20040006044 For therapy and prophylaxis |
| 01/08/2004 | US20040006043 Methods, pharmaceutical compositions and pharmaceutical kits for enhancing the therapeutic efficiency of cancer chemotherapeutic agents |
| 01/08/2004 | US20040006041 Ready-to-use, injectable; stability |
| 01/08/2004 | US20040006032 Vaccination |
| 01/08/2004 | US20040006024 Therapy of vaginitis by administering a polypeptide including an amino acid sequence KPV(lysine-proline-valine) at C-terminus |
| 01/08/2004 | US20040006012 Microemulsion pre-concentrate comprising a difficultly soluble active agent and a carrier medium comprising 1) a hydrophilic phase which comprises dimethylisosorbide and/or a lower alkyl alkanoic ester, 2) a lipophilic phase, and 3) a surfactant |
| 01/08/2004 | US20040006009 Pharmaceutical compositions comprising mannose binding lectin |
| 01/08/2004 | US20040006007 Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides |
| 01/08/2004 | US20040005999 Sustained release preparations of insulin comprising polyamino acid particles, insulin and one or more preservative agents, and a method of preparing such preparations. |
| 01/08/2004 | US20040005998 Producing large lots of final sterile Poly-ICLC suitable for clinical use with reduced toxicity at effective dose levels, and method for using Poly-ICLC to regulate genes, and method for using Poly-ICLC to treat certain human and veterinary |
| 01/08/2004 | US20040005996 Method of producing protein stabilised emulsions comprising the steps of decreasing the pH of a protein solution by the addition of an acidic solution to convert it to a cationic form, heating the solution until the protein is solubilised, |
| 01/08/2004 | US20040005830 Microencapsulated fragrances and methods of coating microcapsules |
| 01/08/2004 | US20040005630 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| 01/08/2004 | US20040005485 Nanostructured powders and related nanotechnology |
| 01/08/2004 | US20040005423 Method of producing structures using centrifugal forces |
| 01/08/2004 | US20040005363 A biodegradable biopolymer material consists of silk fibroin from domesticated silkworm; silk fibroin from wild silkworm; a composite material comprising silk fibroin from domesticated silkworm and silk fibroin from wild silkworm; or a composite |
| 01/08/2004 | US20040005362 Liquid dosage forms of acid labile drugs |
| 01/08/2004 | US20040005361 Pharmaceutical preparations |
| 01/08/2004 | US20040005360 Core-and-shell dosage form or unit in which the core contains API and in which the shell substantially governs the release such as by controlling diffusion of API through the shell. The shell may comprise a release-blocking polymer, and particles |
| 01/08/2004 | US20040005359 Controlled release oral dosage form |
| 01/08/2004 | US20040005358 Formulation is provided which is capable of releasing vasopeptidase inhibitor, preferably omapatrilat or gemopatrilat, in a manner to provide therapeutically effective NEP inhibitory activity and therapeutically effective ACE |
| 01/08/2004 | US20040005357 Extended-release tablets comprising divalproex sodium |
| 01/08/2004 | US20040005356 Paroxetine which is formulated into tablets using a formulation process in which water is absent. |
| 01/08/2004 | US20040005354 Oral trimethobenzamide formulations and methods |
| 01/08/2004 | US20040005353 Delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is |
| 01/08/2004 | US20040005352 Comprising a microsphere including surface mesopores; a lipid bilayer covering at least a portion of the microsphere; and enclosed mesoporous spaces comprising the surface mesopores and respective portions of the lipid bilayer. |
| 01/08/2004 | US20040005351 Cosolvent evaporation methods and compositions for improving the solubility of hydrophobic compounds, including therapeutic agents such as anticancer drugs, polyene antibiotics, antilipidemic agents, and hydrophobic compounds, |
| 01/08/2004 | US20040005345 Formulation for transmucosal vaginal delivery of bisphosphonates. A targeted site delivery of bisphosphonates to the systemic circulation using a vaginal device comprising an improved bisphosphonate formulation for transmucosal |
| 01/08/2004 | US20040005339 Fibrate oral formulation with improved bioavailability when compared to commercially available formulations containing a therapeutically effective dose of fenofibrate or a fenofibrate derivative dissolved in N-alkyl derivative of 2-pyrrolidone, |
| 01/08/2004 | US20040005310 In a receptacle in which the gas pressure is between 1 mbar and atmospheric pressure; especially for a blood coagulation factor, the von Willebrand factor or albumin. |
| 01/08/2004 | US20040005306 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 01/08/2004 | US20040005305 Nutritional composition for treating an immune condition |
| 01/08/2004 | US20040005302 Use of immunoisolating implantable devices enclosing genetically engineered antigen-producing cells for eliciting immune responses against an antigen in a host. |
| 01/08/2004 | US20040005289 Ophthalmic compositions of lubricating eyes and methods for making and using same |
| 01/08/2004 | US20040005275 Polyoxyethylene glycol, fatty acid mono- and diglyceride ester especially for intranasal administration of, e.g., antiemetics or migraine treating agents |
| 01/08/2004 | US20040005256 Atomizing the first solution; introducing the atomized solution into the second solution; and mixing the atomized solution and the second solution to form the product. |
| 01/08/2004 | US20040004030 Catalyst for conversion processes |
| 01/08/2004 | DE10227734A1 Neue Phenylester New phenylester |
| 01/08/2004 | DE10227294A1 Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung Preparations for nasal administration selected, derived from amino acids CGRP-antagonists as well as methods for their preparation |
| 01/08/2004 | DE10226494A1 Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen Film form mucoadhesive dosage forms for administration of cannabis drugs |
| 01/08/2004 | DE10224556A1 1-Dimethylamino- 3-(3-methoxy-phenyl)2-methyl-pentan-3-ol entaltendes Arzneimittel in verschiedenen Formulierungen 1-dimethylamino-3- (3-methoxy-phenyl) 2-methyl-pentan-3-ol entaltendes drug in different formulations |
| 01/08/2004 | DE10057290B4 Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten To be administered enterally supplement for parenteral nutrition or partial enteral / oral nutrition in critically ill patients, chronically ill and malnourished |
| 01/08/2004 | DE10012026B4 Verwendung eines Gels Use of a gel |
| 01/08/2004 | CA2672551A1 Biodegradable block copolymeric compositions for drug delivery |
| 01/08/2004 | CA2492080A1 Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| 01/08/2004 | CA2491543A1 Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability |
| 01/08/2004 | CA2490811A1 Use of organic compounds |
| 01/08/2004 | CA2490683A1 Coating suspensions (comprising osmopolymers, osmagents) for forming an expandable osmotic composition in controlled release dosage forms as well as the corresponding method for providing this osmotic coating |
| 01/08/2004 | CA2490412A1 Oral dosage from comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition |
| 01/08/2004 | CA2490022A1 A platform for transdermal formulations (ptf) |
| 01/08/2004 | CA2489771A1 Biodegradable block copolymeric compositions for drug delivery |
| 01/08/2004 | CA2489688A1 Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton |
| 01/08/2004 | CA2489555A1 Camptothecin-carboxylate formulations |
| 01/08/2004 | CA2489552A1 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| 01/08/2004 | CA2489295A1 Spherical pellet containing a water-soluble active ingredient |
| 01/08/2004 | CA2488526A1 Stable liquid parenteral parecoxib formulation |
| 01/08/2004 | CA2487712A1 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 01/08/2004 | CA2486531A1 Compositions and method for enhanced mucosal delivery of interferon beta |
| 01/08/2004 | CA2482161A1 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| 01/07/2004 | EP1378241A1 Pharmaceutical compositions comprising arsenic for the treatment of melanoma |
| 01/07/2004 | EP1378240A2 Pharmaceutical compositions comprising arsenic for the treatment of multiple myeloma |
| 01/07/2004 | EP1378238A1 Pharmaceutical compositions containing donepezil hydrochloride |
| 01/07/2004 | EP1378237A1 Remedial agent for chronic articular rheumatism |
| 01/07/2004 | EP1378234A1 Effervescent bisphosphonate formulation |
| 01/07/2004 | EP1377673A2 Glycosilated cationic lipids for liposomes used in drug delivery |
| 01/07/2004 | EP1377571A1 Compounds for use in the treatment of skin conditions |
| 01/07/2004 | EP1377321A2 Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque |
| 01/07/2004 | EP1377320A2 Polynucleotide binding complexes comprising sterols and saponins |
| 01/07/2004 | EP1377316A1 Pharmaceutical composition based on macrolides for topical application in ophthalmology |
| 01/07/2004 | EP1377315A2 Pharmaceutical compositions |
| 01/07/2004 | EP1377314A2 Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections |
| 01/07/2004 | EP1377305A1 Tryptophanyl-trna synthetase derived polypeptides useful for the regulation of an-giogenesis |
| 01/07/2004 | EP1377299A2 Transcutaneous immunostimulation |
| 01/07/2004 | EP1377297A2 Degradation-resistant glucocorticosteroid formulations |
| 01/07/2004 | EP1377292A2 Composition for the treatment of night sight problems (halos, coma and glare) comprising aceclidine |
| 01/07/2004 | EP1377284A1 Controlled release arginine formulations |
| 01/07/2004 | EP1377276A2 Timed pulse release composition |
| 01/07/2004 | EP1377275A2 Vaccine for modulating between t1 and t2 immune responses |
| 01/07/2004 | EP1377274A2 Drug delivery system for hydrophobic drugs |
| 01/07/2004 | EP1377273A2 Method for producing an active ingredient concentrate, and an active ingredient concentrate |
| 01/07/2004 | EP1377271A1 Fatty acid and glucolipid based improved stability and high viscosity emulsion which can be used in cosmetics |